Every story in this issue with a short summary, so you can decide what to read before leaving the site. Summaries are written by AI (Claude) only from each publisher's own description and checked by Jev for anything not in that description. They are not full translations. Follow "Read the original" for the full story.
GigHz, a physician-founded software and research company, announced findings from a peer-reviewed study led by its founder.
Read the original →Researchers in China developed a structure-adaptive Belief Rule Base tuned by an improved whale optimization algorithm. The model automates heart disease diagnosis.
Read the original →A scoping review of 65 studies finds that patient-facing AI tools in primary care are widely accessible to the public. Safety and access outcomes remain strikingly under-evaluated.
Read the original →A mobile Copilot classroom at Berkshire Healthcare shows how trusts are turning to automation to close budget gaps. The piece looks at how much must go right before saved minutes become saved money.
Read the original →Patients can upload photos from home for evaluation instead of making hospital visits. The report is dated Oct. 6, 2026.
Read the original →PayZen's State of Healthcare Affordability: The Patient Perspective 2026 focuses on unaffordability, payment options and AI-powered financial guidance.
Read the original →PacBio will generate full-length RNA data from more than 10,000 samples. TychoBio will use the data to train AI models to design treatments for rare diseases.
Read the original →The article says the "AI biotech" label has become increasingly misleading even though AI has transformed drug discovery. Kurma Partners proposes an investment framework that distinguishes three fundamentally different models. Each builds a different asset, creates value differently and requires a different investment lens.
Read the original →BullFrog AI's platform is also being applied to schizophrenia and bipolar disorder. The aim is to discover drug targets for other neuropsychiatric diseases.
Read the original →CDER's new Office of Innovation and Clinical Trial Modernization brings AI and real-world evidence (RWE) policy together under one roof. The description calls this a structural bet that will either accelerate drug development or not.
Read the original →Guide is Spring Health's AI, available before, between and beyond therapy sessions. It is described as private, safety-tested and included in the user's benefit.
Read the original →The UK government said Tuesday that draft guidance on managing changes to AI-enabled medical devices is due by December. A consultation on classifying them is planned by spring 2027. The measures are part of a regulatory overhaul after the government accepted all 44 recommendations issued last month by an independent commission, with the aim of speeding patient access while maintaining safety safeguards.
Read the original →Five institutions, including NEC and Taiho Pharmaceutical, have started a joint project combining quantum computing and AI for next-generation cancer immunotherapy. The project was selected for a demonstration program of the New Energy and Industrial Technology Development Organization and aims to design and optimize neoantigen candidates as cancer treatment targets. The research period is planned from September 2026 to March 2029.
Read the original →